Article

Significant reduction of granulomas in Nrf2-deficient mice infected with Mycobacterium tuberculosis.

The Research Institute of Tuberculosis, Tokyo 204-0022, Japan.
The Indian journal of tuberculosis 04/2010; 57(2):108-13.
Source: PubMed

ABSTRACT We have reported previously that mice deficient in nuclear erythroid 2 p45-related factor 2 (Nrf2), which regulates the expression of antioxidant and detoxification genes, showed significant susceptibility to airway inflammatory responses when exposed to diesel exhaust particles for eight weeks. As disruption of Nrf2 promotes immune cells that stimulate Th2-like immunoresponsiveness, Nrf2-deficient mice may be resistant to M. tuberculosis infection.
Nrf2-deficient mice were infected with M. tuberculosis aerially, and the size of their granulomas and cytokine mRNA expression were compared with those of wild-type mice.
Significant reduction of granuloma formation and tubercle bacilli in granulomas was noted in the deficient mice 27 weeks after infection, concurrently with higher expression of IL-2 and IL-13 mRNA.
It is concluded that Nrf2 inversely regulates M. tuberculosis-induced granuloma development at the late stage.

1 Bookmark
 · 
160 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: 報告番号: ; 学位授与日: 2008-03-24 ; 学位の種別: 修士 ; 学位の種類: 修士(工学) ; 学位記番号: 本論文では低温超電導体であるNbTiを用いた本方式の限流器で問題となっていたサージ電流やインラッシュ電流に対する動作に関して、高温超電導体であるBSCCO線材を用いた試作限流器の動作改善を確認を行った。 まず周波数特性実験の結果より、この試作限流器は周波数が高くなるにつれて動作開始電流値が大きくなることが分かった。この事は、周波数の高い電流に対して、より動作し難いことが分かった。更に実際にインパルス実験を行い、動作の改善が確認できた。続いて交流電流連続通電実験より、各周波数に対して通電サイクルを長くしても動作開始電流値が低下してないことが分かった。温度上昇も計算によって考察し、その結果この銀シースBSCCO線材は冷却特性が良く、温度上昇が抑えられていることが分かった。 更に、復帰特性を実験により調べ、復帰特性が優れていることを確認した。 最後に、18kVAの発電機を含んだ模擬系統での実験が可能な限流器を、新たに設計しその特性を評価する指針を示した。
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This paper reviews new drug targets in the treatment of depression and new drug candidates to treat depression. Depression is characterized by aberrations in six intertwined pathways: (1) inflammatory pathways as indicated by increased levels of proinflammatory cytokines, e.g. interleukin-1 (IL-1), IL-6, and tumour necrosis factor α. (2) Activation of cell-mediated immune pathways as indicated by an increased production of interferon γ and neopterin. (3) Increased reactive oxygen and nitrogen species and damage by oxidative and nitrosative stress (O&NS), including lipid peroxidation, damage to DNA, proteins and mitochondria. (4) Lowered levels of key antioxidants, such as coenzyme Q10, zinc, vitamin E, glutathione, and glutathione peroxidase. (5) Damage to mitochondria and mitochondrial DNA and reduced activity of respiratory chain enzymes and adenosine triphosphate production. (6) Neuroprogression, which is the progressive process of neurodegeneration, apoptosis, and reduced neurogenesis and neuronal plasticity, phenomena that are probably caused by inflammation and O&NS. Antidepressants tend to normalize the above six pathways. Targeting these pathways has the potential to yield antidepressant effects, e.g. using cytokine antagonists, minocycline, Cox-2 inhibitors, statins, acetylsalicylic acid, ketamine, ω3 poly-unsaturated fatty acids, antioxidants, and neurotrophic factors. These six pathways offer new, pathophysiologically guided drug targets suggesting that novel therapies could be developed that target these six pathways simultaneously. Both nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activators and glycogen synthase kinase-3 (GSK-3) inhibitors target the six above-mentioned pathways. GSK-3 inhibitors have antidepressant effects in animal models of depression. Nrf2 activators and GSK-3 inhibitors have the potential to be advanced to phase-2 clinical trials to examine whether they augment the efficacy of antidepressants or are useful as monotherapy.
    Inflammopharmacology 01/2012; 20(3):127-50.

Full-text (2 Sources)

Download
46 Downloads
Available from
May 30, 2014